Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.700
-0.060 (-3.41%)
At close: Apr 28, 2026, 4:00 PM EDT
1.730
+0.030 (1.76%)
After-hours: Apr 28, 2026, 6:16 PM EDT
Pyxis Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 13.86 | 16.15 | - | - | - | |
| Revenue Growth (YoY) | -14.17% | - | - | - | - | |
| Cost of Revenue | 2.39 | 0.48 | - | - | - | |
| Gross Profit | 11.47 | 15.67 | - | - | - | |
| Selling, General & Admin | 19.62 | 22.49 | 30.83 | 37.35 | 18.66 | |
| Research & Development | 73.7 | 58.75 | 49.59 | 86.13 | 51.05 | |
| Operating Expenses | 93.32 | 81.24 | 80.42 | 123.48 | 69.72 | |
| Operating Income | -81.85 | -65.57 | -80.42 | -123.48 | -69.72 | |
| Interest & Investment Income | 3.61 | 7.04 | 6.63 | 2.76 | 0.02 | |
| Earnings From Equity Investments | - | - | - | - | -0.23 | |
| Other Non Operating Income (Expenses) | - | - | - | - | -6.05 | |
| EBT Excluding Unusual Items | -78.24 | -58.53 | -73.79 | -120.72 | -75.98 | |
| Pretax Income | -78.24 | -79.5 | -73.79 | -120.72 | -75.98 | |
| Income Tax Expense | 1.39 | -2.16 | - | - | - | |
| Net Income | -79.62 | -77.33 | -73.79 | -120.72 | -75.98 | |
| Net Income to Common | -79.62 | -77.33 | -73.79 | -120.72 | -75.98 | |
| Shares Outstanding (Basic) | 62 | 58 | 40 | 33 | 8 | |
| Shares Outstanding (Diluted) | 62 | 58 | 40 | 33 | 8 | |
| Shares Change (YoY) | 6.33% | 46.46% | 20.80% | 288.93% | 724.14% | |
| EPS (Basic) | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 | |
| EPS (Diluted) | -1.28 | -1.32 | -1.85 | -3.65 | -8.95 | |
| Free Cash Flow | -63.51 | -57.91 | -77.44 | -95.73 | -35.87 | |
| Free Cash Flow Per Share | -1.02 | -0.99 | -1.94 | -2.90 | -4.22 | |
| Gross Margin | 82.77% | 97.06% | - | - | - | |
| Operating Margin | -590.60% | -406.11% | - | - | - | |
| Profit Margin | -574.55% | -478.95% | - | - | - | |
| Free Cash Flow Margin | -458.30% | -358.66% | - | - | - | |
| EBITDA | -77.33 | -62.59 | -78.49 | -122.77 | -69.07 | |
| D&A For EBITDA | 4.51 | 2.98 | 1.93 | 0.71 | 0.65 | |
| EBIT | -81.85 | -65.57 | -80.42 | -123.48 | -69.72 | |
| Revenue as Reported | 13.86 | 16.15 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.